NeoGenomics, Inc.

NeoGenomics, Inc.

NEO

$17.10

Updated: 04/11/2026, 20:06:22

Market Cap
$2.23B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US

No historical data available

Company Profile

NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.

USD
NASDAQ
CEO: Anthony Zook
Employees: 2,500
https://www.neogenomics.com
Asset Summaries
Latest generated summaries for NEO

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for NEO.
Share price
$17.10
Market cap
$2.23B
Exchange
NASDAQ
Currency
USD
CEO
Anthony Zook
Employees
2,500
IPO date
16/03/2004
Beta
1.834
Last dividend
$0.00
Day range
$16.60 – $17.39
52-week range
$7.07 – $20.15
1-day performance
1.60%
1-year performance
141.87%
Current drawdown (1Y)
-15.14%
CIK
0001077183
CUSIP
64049M209
ISIN
US64049M2098
Created
07/12/2025, 05:25:20
Last update
04/11/2026, 20:06:22

Track NeoGenomics, Inc. with an AI analyst

See which prediction-market events move NEO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to NEO from your Railway `news_articles` table.

NeoGenomics Inc (NEO) Stock Up 6.5% and Still Undervalued -- GF Score: 68/100

GuruFocus • STOCK • 28/05/2026, 22:54:00

Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares

GlobeNewsWire • STOCK • 20/05/2026, 18:20:00

NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 29/04/2026, 05:51:32

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

Business Wire • STOCK • 23/04/2026, 09:05:00

Neo Energy Metals shares surge 33% as ex-Sibanye chief Froneman joins as chairman

Proactive Investors • STOCK • 22/04/2026, 06:45:59

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

Business Wire • STOCK • 13/04/2026, 09:05:00

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

Business Wire • STOCK • 07/04/2026, 09:05:00

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

Business Wire • STOCK • 25/02/2026, 08:05:00

Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology

Business Wire • STOCK • 23/02/2026, 07:00:00

NeoGenomics to Participate in Upcoming Investor Conferences

Business Wire • STOCK • 18/02/2026, 08:05:00

NeoGenomics, Inc. (NASDAQ:NEO) Financial Performance Analysis

Market Data • Market Data • 17/02/2026, 18:00:05

NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates

Zacks Investment Research • STOCK • 17/02/2026, 10:16:08